Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivoHuman ex vivo data ...

Absci (ABSI) unveiled new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor. The data demonstrate that ...

The Phase 1/2a clinical trial will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ABS-201. Interim data are expected in the second half ...

Absci Corporation (NASDAQ:ABSI) pioneers AI-driven biologic drug creation, advancing biotechnology through innovation.

Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia December 11, 2025 10:00 AM ESTCompany ...

Absci shares rose after the artificial-intelligence pharmaceutical company said the first volunteers have received doses in its Phase 1/2 trial for a pattern baldness treatment. The stock rose 17% to ...

Absci says it is on track to advance its first antibody developed through its generative artificial intelligence (AI)-based platform to IND stage within the next 24 months, after the company disclosed ...

Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in ...

“Absci really wants to become the Google Index search of protein-based drug discovery and biomanufacturing for large pharmas and biotechs,” founder and CEO Sean McClain declared to GEN Edge. Since it ...

Fintel reports that on December 12, 2025, Needham reiterated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation.

Vancouver startup Absci debuted on Wall Street Thursday, with investors pouring money into the biotech company at its initial public offering. Shares jumped 35% from the $16 offering price to close at ...